Cell Therapeutics' Drug Gets Fast Track
Posted on: Monday, 7 May 2007, 12:00 CDT
Cell Therapeutics said Monday the U.S. Food and Drug Administration granted fast track status to pixantrone, a non-Hodgkin's lymphoma treatment.
The fast track designation applies to pixantrone for relapsed or refractory indolent non-Hodgkin's lymphoma, or NHL. The compound has previously received fast track status for aggressive NHL.
This designation for indolent NHL is an important step in the development of this product and may help us bring this potentially life-saving drug to patients more quickly, said James Bianco, Cell Therapeutics' president and CEO.
Cell Therapeutics said in a phase 3 trial pixantrone plus rituximab improved time to tumor progression in relapsed or refractory indolent NHL patients compared to rituximab alone.
Source: United Press International
Related Articles
- Pixantrone Granted Fast Track Designation By FDA for Relapsed Indolent NHL Patients
- Cell Therapeutics' Xyotax Fast Tracked
- Cell Therapeutics Cancer Drug Gains Fast Track Status
- Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn's Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial
- Allos' T-Cell Lymphoma Drug on Fast Track
- Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-Cell Lymphoma
- FDA Grants Point Therapeutics' Talabostat Fast Track Status
- Point Therapeutics Receives Fast Track Designation for Talabostat
- Cell Therapeutics Cancer Drug Fast Tracked
 |
 |
User Comments (0)
RSS Feeds